PureTech snags $11.4M from DOD to test hormone drug in rare brain disease

The Department of Defense has awarded PureTech Health up to $11.4 million to test an experimental therapy for a rare neurodegenerative disease called fragile X-associated tremor ataxia syndrome (FXTAS), the Boston biotech told Endpoints News.

The disease, which PureTech executives say is underdiagnosed, predominantly affects men in their…
Click here to view original post